Ameriprise
ARQT icon

Ameriprise’s Arcutis Biotherapeutics ARQT Stock Holding History

Ameriprise’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.76M Buy
295,997
+194,323
+191% +$4.53M ﹤0.01% 2236
2026
Q1 		$2.4M Buy
101,674
+2,848
+3% +$72.7K ﹤0.01% 2865
2025
Q4 		$2.87M Sell
98,826
-359
-0.4% -$9.19K ﹤0.01% 2804
2025
Q3 		$1.87M Buy
99,185
+141
+0.1% +$2.22K ﹤0.01% 3036
2025
Q2 		$1.39M Sell
99,044
-14,335
-13% -$201K ﹤0.01% 3135
2025
Q1 		$1.77M Sell
113,379
-26,550
-19% -$374K ﹤0.01% 2957
2024
Q4 		$1.95M Buy
139,929
+50,662
+57% +$555K ﹤0.01% 2942
2024
Q3 		$830K Buy
89,267
+11,861
+15% +$117K ﹤0.01% 3291
2024
Q2 		$720K Sell
77,406
-16,534
-18% -$150K ﹤0.01% 3302
2024
Q1 		$931K Sell
93,940
-985,640
-91% -$7.36M ﹤0.01% 3192
2023
Q4 		$3.49M Buy
+1,079,580
New +$2.93M ﹤0.01% 2589
2023
Q3 		– Sell
-337,052
Closed -$3.21M – 3888
2023
Q2 		$3.21M Sell
337,052
-517,682
-61% -$5.75M ﹤0.01% 2632
2023
Q1 		$9.4M Buy
854,734
+41,112
+5% +$595K ﹤0.01% 1822
2022
Q4 		$12M Buy
813,622
+158,944
+24% +$2.78M ﹤0.01% 1587
2022
Q3 		$12.5M Buy
654,678
+110,490
+20% +$2.5M ﹤0.01% 1490
2022
Q2 		$11.6M Buy
544,188
+113,926
+26% +$2.34M ﹤0.01% 1620
2022
Q1 		$8.29M Buy
430,262
+213,859
+99% +$3.62M ﹤0.01% 2058
2021
Q4 		$4.49M Sell
216,403
-145,632
-40% -$2.9M ﹤0.01% 2547
2021
Q3 		$8.65M Buy
362,035
+7,155
+2% +$163K ﹤0.01% 1970
2021
Q2 		$9.69M Buy
354,880
+37,677
+12% +$1.06M ﹤0.01% 1963
2021
Q1 		$9.18M Buy
317,203
+202,086
+176% +$6.31M ﹤0.01% 1953
2020
Q4 		$3.24M Sell
115,117
-169,329
-60% -$4.15M ﹤0.01% 2547
2020
Q3 		$8.33M Buy
284,446
+6,427
+2% +$172K ﹤0.01% 1681
2020
Q2 		$8.41M Buy
278,019
+23,580
+9% +$681K ﹤0.01% 1658
2020
Q1 		$7.58M Buy
+254,439
New +$6.84M ﹤0.01% 1594

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameriprise's ARQT Position: Q2 2026 in Review

Ameriprise increased its Arcutis Biotherapeutics (ARQT) stake by 191% in Q2 2026, buying an estimated $4.53M and bringing the position to 295,997 shares worth $7.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Ameriprise first reported a position in ARQT in Q1 2020 and has held it in 25 quarters since. The position peaked at $12.5M in Q3 2022. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Ameriprise held 295,997 shares of Arcutis Biotherapeutics worth $7.76M as of Q2 2026.
  • Ameriprise bought 194,323 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.53M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2236 holding.
  • Ameriprise first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 25 quarters since.
  • Ameriprise's Arcutis Biotherapeutics position peaked at $12.5M in Q3 2022.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.